The “Made-in-Canada CAR-T” platform cell manufacturing program uses a GMP-enabled manufacturing device to produce a cell therapy dose in 7–10 days, and it has already been used for 50 patients at less than 1/10 of the cost of a commercial product (e.g., $40,000 vs. $475,000 per dose of CD19 CAR-T for certain cancer patients) [23]. This evidence concerns the gene CD19 and cancer.